Here’s Why Clearbridge Growth Strategy Sold AbbVie (ABBV)

2 months ago 16

Soumya Eswaran

Fri, Apr 11, 2025, 7:16 AM 3 min read

ClearBridge Investments, an concern absorption company, released its “ClearBridge Growth Strategy” archetypal 4th 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. First 4th of 2025 witnessed crisp equities merchantability disconnected owed the displacement retired of mega caps. There was a comparative outperformance of mid headdress maturation stocks implicit ample and tiny headdress maturation during the archetypal 4th correction which indicates the broadening of market, that presents charismatic opportunities for precocious progressive stock managers. In the quarter, the ClearBridge Growth Strategy marginally underperformed its Russell Midcap Growth Index benchmark. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its archetypal 4th 2025 capitalist letter, ClearBridge Growth Strategy emphasized stocks specified arsenic AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is simply a research-based biopharmaceutical company. The one-month instrumentality of AbbVie Inc. (NYSE:ABBV) was -17.74%, and its shares gained 7.35% of their worth implicit the past 52 weeks. On April 10, 2025, AbbVie Inc. (NYSE:ABBV) banal closed astatine $174.20 per stock with a marketplace capitalization of $308.16 billion.

ClearBridge Growth Strategy stated the pursuing regarding AbbVie Inc. (NYSE:ABBV) successful its Q1 2025 capitalist letter:

"The income of AbbVie Inc. (NYSE:ABBV) and Ionis Pharmaceuticals consolidate our exposures wrong wellness attraction toward companies with much charismatic and predictable semipermanent maturation prospects. Both companies look slowing maturation — AbbVie owed to the nonaccomplishment of exclusivity of Humira and the maturing of respective of their existing franchises and Ionis owed to waning income for its cause for spinal muscular atrophy, Spinraza. We took vantage of the caller rally successful AbbVie to exit arsenic expanding reliance connected pipeline and caller merchandise execution to enactment stock appreciation marque the risk/reward little charismatic from here."

Is AbbVie Inc. (ABBV) the Best Stock for 15 Years?

A pharmacist handing retired a pharmaceutical cause to a diligent successful a cause store oregon chemist.

AbbVie Inc. (NYSE:ABBV) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 85 hedge money portfolios held AbbVie Inc. (NYSE:ABBV) astatine the extremity of the 4th fourth compared to 68 successful the 3rd quarter. AbbVie Inc. (NYSE:ABBV) reported full-year adjusted net per stock of $10.12, which is $0.49 supra the archetypal guidance midpoint. While we admit the imaginable of AbbVie Inc. (NYSE:ABBV) arsenic an investment, our condemnation lies successful the content that AI stocks clasp greater committedness for delivering higher returns, and doing truthful wrong a shorter timeframe. If you are looking for an AI banal that is arsenic promising arsenic NVIDIA but that trades astatine little than 5 times its earnings, cheque retired our study astir the cheapest AI stock.

Read Entire Article